1
|
Çöpelci Y, Gündüz UR, Dinç B, Belen NH, Gündüz Ş. Effects of Primary Tumor Resection on Metastatic Breast Cancer Survival and the Predictive Power of Neutrophil: Lymphocyte Ratio on Prognosis. Eur J Breast Health 2021; 17:322-327. [PMID: 34651110 DOI: 10.4274/ejbh.galenos.2021.2021-3-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2021] [Accepted: 03/07/2021] [Indexed: 12/01/2022]
Abstract
Objective The aim was to investigate the effect of primary tumor resection (PTR) on survival in metastatic breast cancer patients and to assess the power of the neutrophil-to-lymphocyte ratio (NLR) regarding the prediction of prognosis in this patient group. Materials and Methods Female patients diagnosed with and starting treatment for metastatic breast cancer from 2003 to 2016 in the general surgery and oncology clinics at a single center were retrospectively reviewed. Pre-treatment NLR value and survival situations were evaluated. Results A total of 117 patients were enrolled. The disease-specific survival (DSS) of the patients was 41.4 months. When stratified into PTR and systemic treatment (ST) groups, there was no difference in the survival (p = 0.054); 43.5 months in the PTR group vs 30.7 months in the ST group. When hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative subgroups were analyzed, DSS was significantly longer (p = 0.02) in the PTR group (55.4 months) compared to the ST group (41.8 months). Finally, in patients with an NLR of <2.3, DSS was significantly longer (p = 0.03) in the PTR group (56.1 months) compared to the ST group (25.2 months). Conclusion These results suggest that DSS can be increased with PTR in selected patients with a diagnosis of metastatic breast cancer. NLR may be useful in selecting patients for appropraite treatment modality.
Collapse
Affiliation(s)
- Yaşar Çöpelci
- Department of General Surgery, University of Health Sciences Turkey, Erzurum Regional Training and Research Hospital, Erzurum, Turkey
| | - Umut Rıza Gündüz
- Department of General Surgery, University of Health Sciences Turkey, Antalya Training and Research Hospital, Antalya, Turkey
| | - Bülent Dinç
- Department of General Surgery, University of Health Sciences Turkey, Antalya Training and Research Hospital, Antalya, Turkey
| | - Nurhan Haluk Belen
- Department of General Surgery, University of Health Sciences Turkey, Antalya Training and Research Hospital, Antalya, Turkey
| | - Şeyda Gündüz
- Clinic of Medical Oncology, Memorial Antalya Hospital, Antalya, Turkey
| |
Collapse
|
2
|
Demir A, Mandel NM, Paydas S, Demir G, Er Ö, Turhal NS, Bavbek S, Eralp Y, Saip PM, Güler EN, Aydıner A, Oyan Uluç B, Kılıçkap S, Üskent N, Karadurmuş N, Kaplan MA, Yanmaz MT, Demir H, Alan Ö, Korkmaz T, Olgun P, Sönmez Uysal Ö, Altundağ K, Gündüz Ş, Günaldı M, Sarı M, Beypınar İ, Başaran G. Efficacy of Palbociclib and Endocrine Treatment in Heavily Pretreated Hormone Receptor-positive/HER2-negative Advanced Breast Cancer: Retrospective Multicenter Trial. Balkan Med J 2020; 37:104-107. [PMID: 31970972 PMCID: PMC7094190 DOI: 10.4274/balkanmedj.galenos.2020.2019.11.143] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Background: The synthesis of CDK4/6 inhibitors with endocrine treatment in two series of treatment has been widely accepted as the standard for patients with estrogen receptor-positive metastatic breast cancer. In spite of this, the activity of CDK4/6 inhibitors in patients with metastatic breast cancer who have progressed despite receiving multiple lines of treatment is not well understood. Aims: To report the activity and safety of a CDK4/6 inhibitor (palbociclib) in patients in whom at least three lines of treatment for ER+ metastatic breast cancer had failed. Study Design: Multicenter retrospective observational cohort study. Methods: In this retrospective observational cohort study, we included 43 patients who received palbociclib after at least three lines of systemic treatment for ER+/HER2− metastatic breast cancer. Results: The median progression-free survival in our population was 7 months (25th-75th percentile, 4-10), and the median overall survival was 11 months (25th-75th percentile, 6-19). Although there were some adverse events, palbociclib was generally well tolerated, so dose reduction was needed for only six patients (14%). Conclusion: The efficacy of palbociclib among heavily treated hormone receptor-positive/HER2− patients with advanced breast cancer was acceptable in terms of clinical benefit, and it was generally well tolerated among this population.
Collapse
Affiliation(s)
- Atakan Demir
- Department of Medical Oncology, Acıbadem University, İstanbul, Turkey
| | | | - Semra Paydas
- Department of Medical Oncology, Çukurova University School of Medicine, Adana, Turkey
| | - Gökhan Demir
- Department of Medical Oncology, Acıbadem University, İstanbul, Turkey
| | - Özlem Er
- Department of Medical Oncology, Acıbadem University, İstanbul, Turkey
| | | | | | - Yeşim Eralp
- Department of Medical Oncology, Acıbadem University, İstanbul, Turkey
| | - Pınar Mualla Saip
- Department of Medical Oncology, İstanbul University Oncology Institute, İstanbul, Turkey
| | - Emine Nilüfer Güler
- Department of Medical Oncology, Hacettepe University School of Medicine, Ankara, Turkey
| | - Adnan Aydıner
- Department of Medical Oncology, İstanbul University Oncology Institute, İstanbul, Turkey
| | - Başak Oyan Uluç
- Department of Medical Oncology, Acıbadem University, İstanbul, Turkey
| | - Sadettin Kılıçkap
- Department of Medical Oncology, Hacettepe University School of Medicine, Ankara, Turkey
| | - Necdet Üskent
- Clinic of Oncology, Anadolu Medical Center Hospital, Kocaeli, Turkey
| | - Nuri Karadurmuş
- Clinic of Medical Oncology T.C. Ministry of Health Gülhane Training and Research Hospital, Ankara, Turkey
| | - Mehmet Ali Kaplan
- Department of Medical Oncology, Dicle University School of Medicine, Diyarbakır, Turkey
| | | | - Hacer Demir
- Department of Medical Oncology Afyon Kocatepe University School of Medicine, Afyon, Turkey
| | - Özkan Alan
- Tekirdağ State Hospital, Tekirdağ, Turkey
| | - Taner Korkmaz
- Department of Medical Oncology, Acıbadem University, İstanbul, Turkey
| | - Polat Olgun
- Near East University Hospital, Lefkoşa, TRNC
| | | | | | | | - Meral Günaldı
- Clinic of Medical Oncology, Florya Medical Park Hospital, İstanbul, Turkey
| | | | - İsmail Beypınar
- Department of Medical Oncology Afyon Kocatepe University School of Medicine, Afyon, Turkey
| | - Gül Başaran
- Department of Medical Oncology, Acıbadem University, İstanbul, Turkey
| |
Collapse
|
3
|
Demir A, Molinas Mandel N, Paydas S, Demir G, Er Ö, Turhal NS, Bavbek S, Eralp Y, Saip PM, Güler N, Aydıner A, Oyan Uluç B, Kılıçkap S, Üskent N, Karadurmuş N, Kaplan MA, Teoman M, Yanmaz T, Demir H, Alan Ö, Korkmaz T, Olgun P, Sönmez Uysal Ö, Altundağ K, Gündüz Ş, Günaldı M, Sarı M, Beypınar İ, Başaran G. Efficacy of Palbociclib and Endocrine Treatment in Heavily Pretreated Hormone Receptor-positive Her2-negative Advanced Breast Cancer: Retrospective Multicenter Trial. Balkan Med J 2020. [DOI: 10.4274/balkanmedj.galenos.2019.11.143] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
|
4
|
Sürer Budak E, Yıldırım Ş, Yıldız S, Öner AO, Gündüz Ş. Two Uncommon Sites of Metastasis: Breast and Hypophysis Metastases of Head and Neck Adenoid Cystic Carcinoma Detected by FDG PET/CT. Mol Imaging Radionucl Ther 2017; 26:120-123. [PMID: 28976335 PMCID: PMC5643940 DOI: 10.4274/mirt.06025] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
Abstract
Adenoid cystic carcinoma (ACC) is a rare epithelial malignancy arising from secretory glands, particularly the salivary glands. It tends to invade nerves and has a high potential for distant hematogenous metastasis, especially to the lungs, bone, liver and brain. The breast and hypophysis are not common sites of ACC metastatic disease. Herein, we report a case of ACC of the head and neck region with two unusual sites of metastases, the hypophysis and breast.
Collapse
Affiliation(s)
- Evrim Sürer Budak
- Antalya Training and Research Hospital, Clinic of Nuclear Medicine, Antalya, Turkey
| | - Şenay Yıldırım
- Antalya Training and Research Hospital, Clinic of Pathology, Antalya, Turkey
| | - Sevim Yıldız
- Antalya Training and Research Hospital, Clinic of Radiology, Antalya, Turkey
| | - Ali Ozan Öner
- Afyon Kocatepe University Faculty of Medicine, Clinic of Nuclear Medicine, Afyon, Turkey
| | - Şeyda Gündüz
- Antalya Training and Research Hospital, Clinic of Medical Oncology, Antalya, Turkey
| |
Collapse
|
5
|
Mutlu H, Salim DK, Gündüz Ş, Eryılmaz MK, Musri FY, Coşkun HŞ. Docetaxel plus cisplatin plus fluorouracil versus carboplatin plus fluorouracil-cetuximab in first-line setting in patients with recurrent or metastatic head and neck squamous cell cancer who did not previously receive neoadjuvant or adjuvant chemotherapy, which is standard? J Cancer Res Ther 2017; 13:510-513. [PMID: 28862218 DOI: 10.4103/0973-1482.161933] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BACKGROUND The prognosis of recurrent or metastatic head and neck squamous cell cancer (HNSCC) is very poor. In the present retrospective study, we compared the impact of docetaxel plus cisplatin plus fluorouracil (TCF), and cisplatin plus fluorouracil plus cetuximab (CF-Ctx) regimens on the prognosis of patients with recurrent or metastatic HNSCC in first-line. MATERIALS AND METHODS A total of 70 patients were evaluated as two groups, according to treatment protocol: TCF (n: 47) and CF-Ctx (n: 23). The groups were compared regarding survival. RESULTS The median progression-free survival was 7.3 and 8.3 months, TCF and CF-Ctx groups, respectively, (P = 0.280). The median overall survival (OS) was 15.6 and 9.3 months for TCF and CF-Ctx groups, respectively, (P = 0.029). The dose reduction and using of granulocyte colony stimulating factor were significantly higher in TCF group (P = 0.048 and P = 0.018, respectively). CONCLUSION In first-line setting, TCF regimen is superior to CF-Ctx regimen in terms of OS in patients with recurrent or metastatic HNSCC, who did not previously receive neoadjuvant or adjuvant chemotherapy.
Collapse
Affiliation(s)
- Hasan Mutlu
- Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey
| | - Derya Kıvrak Salim
- Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey
| | - Şeyda Gündüz
- Department of Antalya Research and Training Hospital, Antalya, Turkey
| | | | - Fatma Yalçın Musri
- Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey
| | - Hasan Şenol Coşkun
- Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey
| |
Collapse
|
6
|
Süren D, Yildirim M, Sayiner A, Alikanoğlu AS, Atalay I, Gündüz UR, Kaya V, Gündüz Ş, Oruç MT, Sezer C. Expression of claudin 1, 4 and 7 in thyroid neoplasms. Oncol Lett 2017; 13:3722-3726. [PMID: 28529587 DOI: 10.3892/ol.2017.5916] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2015] [Accepted: 01/06/2017] [Indexed: 01/28/2023] Open
Abstract
The distinction of thyroid carcinoma from benign thyroid neoplasm, as well as the subtyping of papillary carcinoma (PC) and follicular carcinoma (FC), may be performed histopathologically in the majority of cases. However, in certain cases, it is difficult to histopathologically distinguish between PC and FC, as well as follicular adenoma (FA), FC and the dominant nodule of multinodular goiter (MNG-DN). The present study aimed to determine the roles of the expression levels of the tight junction proteins claudin 1, 4 and 7 in the differential diagnosis of PC, FC, FA, MNG-DN, medullary carcinoma (MC) and anaplastic carcinoma (AC). The current study included 114 cases of histopathologically diagnosed thyroid neoplasia, which were distributed as follows: 29 FA, 18 MNG-DN, 47 PC, 10 FC, 5 MC and 5 AC. The expression levels of claudin 1, 4 and 7 were examined using immunohistochemical methods. The results revealed a significant difference in claudin 1 expression between malignant and benign thyroid neoplasms (P<0.001). Claudin 1 expression was not detected in any of the MNG-DN cases, and no significant difference in claudin 1 expression levels was identified between FA and FC (P=0.653). However, a statistically significant difference was observed between FC and PC (P<0.001). Claudin 4 expression did not differ between malignant and benign thyroid neoplasms, neither between MNG-DN, FA and FC, nor between FC and PC (P=0.068, P=0.502 and P=0.481, respectively). Claudin 7 exhibited positive immunohistochemical staining in 107 patients (94%); however, no significant difference in claudin 7 expression §levels was identified between malignant and benign thyroid neoplasms among MNG-DN, FA and FC (malignant, P=0.135; benign, P=0.470). Claudin 7 exhibited positive staining in all PC and FC cases. Therefore, claudin 1 expression levels may be useful in distinguishing cases of FC and PC with overlapping histopathological features, and provide a novel immunohistochemical marker for the subtyping of thyroid carcinoma.
Collapse
Affiliation(s)
- Dinç Süren
- Department of Pathology, University of Health Sciences, Antalya Education and Research Hospital, Antalya 07050, Turkey
| | - Mustafa Yildirim
- Department of Medical Oncology, Medical Park Hospital, Gaziantep 27100, Turkey
| | - Alper Sayiner
- Department of Pathology, University of Health Sciences, Antalya Education and Research Hospital, Antalya 07050, Turkey
| | - Arsenal Sezgin Alikanoğlu
- Department of Pathology, University of Health Sciences, Antalya Education and Research Hospital, Antalya 07050, Turkey
| | - Irem Atalay
- Department of Pathology, University of Health Sciences, Antalya Education and Research Hospital, Antalya 07050, Turkey
| | - Umut Riza Gündüz
- Department of General Surgery, University of Health Sciences, Antalya Education and Research Hospital, Antalya 07050, Turkey
| | - Vildan Kaya
- Department of Radiation Oncology, Süleyman Demirel University, Isparta 32260, Turkey
| | - Şeyda Gündüz
- Department of Medical Oncology, University of Health Sciences, Antalya Education and Research Hospital, Antalya 07050, Turkey
| | - Mehmet Tahir Oruç
- Department of General Surgery, University of Health Sciences, Antalya Education and Research Hospital, Antalya 07050, Turkey
| | - Cem Sezer
- Department of Pathology, University of Health Sciences, Antalya Education and Research Hospital, Antalya 07050, Turkey
| |
Collapse
|
7
|
Kargı A, Demirpençe Ö, Gündüz Ş, Göktaş S, Alikanoǧlu AS, Yıldırım M. Serum levels of HMGB1 have a diagnostic role in metastatic renal cell cancer. Cancer Biomark 2017; 17:17-20. [PMID: 27062570 DOI: 10.3233/cbm-160611] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
RCC constitutes approximately 90% of all renal malignancies and 2-3% of all malignant tumours in adults. In spite of the improvement in radiologic methods, nearly 30% of the early metastatic RCC patients are incidentally diagnosed. HMGB1 is an extracellular signalling molecule that plays a role both in inflammation and carcinogenesis. Patients who were followed in Medical Oncology Departments of Denizli Government Hospital and Antalya Education and Research Hospital with a histopathological diagnosis of RCC between years 2010-2012 were enrolled in this study. HMGB1 levels were also assessed in a manually performed quantitative sandwich-enzyme-linked immunosorbent assay (ELISA) assay kit. In our study, we showed that the serum level of HMGB1, whether 149.9 pg/ml or not is important in differential diagnosis between patient and control group.
Collapse
|
8
|
Müsri FY, Mutlu H, Karaağaç M, Eryilmaz MK, Gündüz Ş, Artaç M. Primary Tumor Resection and Survival in Patients with Stage IV Gastric Cancer. J Gastric Cancer 2016; 16:78-84. [PMID: 27433392 PMCID: PMC4944006 DOI: 10.5230/jgc.2016.16.2.78] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/14/2015] [Revised: 04/27/2016] [Accepted: 05/04/2016] [Indexed: 12/18/2022] Open
Abstract
Purpose The aim of this study was to determine whether surgical resection of the primary tumor contributes to survival in patients with metastatic gastric cancer. Materials and Methods A total of 288 patients with metastatic gastric cancer from the Akdeniz University, Antalya Training and Research Hospital, and the Meram University of Konya database were retrospectively analyzed. The effect of primary tumor resection on survival of patients with metastatic gastric cancer was investigated using the log-rank test. Kaplan-Meier survival estimates were calculated. Multivariate analysis was performed using Cox proportional hazards regression modeling. Results The median overall survival was 12.0 months (95% confidence intewrval [CI], 10.4~13.6 months) and 7.8 months (95% CI, 5.5~10.0 months) for patients with and without primary tumor resection, respectively (P<0.001). The median progression-free survival was 8.3 months (95% CI, 7.1~9.5 months) and 6.2 months (95% CI, 5.8~6.7 months) for patients with and without primary tumor resection, respectively (P=0.002). Conclusions Non-curative gastrectomy in patients with metastatic gastric cancer might increase their survival rate regardless of the occurrence of life-threatening tumor-related complications.
Collapse
Affiliation(s)
- Fatma Yalçin Müsri
- Department of Medical Oncology, Faculty of Medicine, Akdeniz University, Antalya, Turkey
| | - Hasan Mutlu
- Department of Medical Oncology, Faculty of Medicine, Akdeniz University, Antalya, Turkey
| | - Mustafa Karaağaç
- Department of Medical Oncology, Faculty of Medicine, Meram University, Konya, Turkey
| | | | - Şeyda Gündüz
- Department of Medical Oncology, Antalya Training and Research Hospital, Antalya, Turkey
| | - Mehmet Artaç
- Department of Medical Oncology, Faculty of Medicine, Meram University, Konya, Turkey
| |
Collapse
|
9
|
Merdin A, Merdin FA, Gündüz Ş, Bozcuk H, Coşkun HŞ. Opioid endocrinopathy: A clinical problem in patients with cancer pain. Exp Ther Med 2016; 11:1819-1822. [PMID: 27168810 DOI: 10.3892/etm.2016.3156] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2014] [Accepted: 11/25/2015] [Indexed: 11/05/2022] Open
Abstract
Opioids are commonly used in cancer pain management. The present study aimed to investigate the occurrence of endocrine dysfunction in patients with cancer pain treated with opioids. The study included 20 patients with cancer-associated pain. All data were obtained from malignant tumors diagnosed and followed up at the Oncology Clinic of Akdeniz University Hospital (Akdeniz, Turkey) between May 2009 and December 2013. Serum samples were collected to determine the levels of hypophyseal, gonadal and thyroid hormones. The inclusion criteria for the study were as follows: Chronic cancer pain, daily treatment with a morphine equivalent daily dose (MEDD) of ≥25 mg/dl for ≥1 month, and a visual analog score of <2. All independent predictors were evaluated using logistic regression analysis. The results did not demonstrate any significant association between MEDD and gender, or the levels of adrenocorticotropic hormone, cortisol, prolactin, thyroid-stimulating hormone, free thyroxine, follicle-stimulating hormone and luteinizing hormone. However, the levels of testosterone (P=0.040) and of free testosterone (P=0.041) were significantly affected by the MEDD. Conversely, prolactin levels were demonstrated to significantly increase with MEDD (P=0.083). The results also indicated that the required opioid analgesic dose and MEDD were significantly affected by age (P≤0.001). Opioid therapy in patients with cancer may inhibit gonadal function and cause hyperprolactinemia.
Collapse
Affiliation(s)
- Alparslan Merdin
- Department of Internal Medicine, Akdeniz University Hospital, Antalya 07058, Turkey
| | - Fatma Avci Merdin
- Department of Internal Medicine, Akdeniz University Hospital, Antalya 07058, Turkey
| | - Şeyda Gündüz
- Department of Medical Oncology, Antalya Education and Research Hospital, Antalya 07070, Turkey
| | - Hakan Bozcuk
- Department of Internal Medicine, Division of Oncology, Akdeniz University Hospital, Antalya 07058, Turkey
| | - Hasan Şenol Coşkun
- Department of Internal Medicine, Division of Oncology, Akdeniz University Hospital, Antalya 07058, Turkey
| |
Collapse
|
10
|
Mutlu H, Arslan D, Gündüz Ş, Tural D, Büyükçelik A, Benderli Cihan Y, Aslan T, Bozcuk H, Şenol Coşkun H. The Optimal Treatment Modality in Patients with T4N2M0 Non-Small Cell Lung Cancer: The Best Choice May Be Definitive Chemoradiotherapy Followed by Consolidation Chemotherapy. Chemotherapy 2015; 60:107-111. [PMID: 25721008 DOI: 10.1159/000371414] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2014] [Accepted: 12/08/2014] [Indexed: 11/19/2022]
Abstract
BACKGROUND Stage IIIB non-small cell lung cancer (NSCLC) consists of T4N2M0 and TXN3M0 NSCLC. In the present study, we aimed to evaluate the efficacy of different treatment strategies on the survival of patients with radiologically confirmed T4N2M0 NSCLC. METHODS A total of 145 patients were evaluated in three groups according to the treatment protocol: induction chemotherapy followed by chemoradiotherapy (induction group); chemoradiotherapy (CRT group), and chemoradiotherapy followed by consolidation chemotherapy (consolidation group). The groups were compared regarding survival. RESULTS The median progression-free survival (PFS) was 10.9, 10.8 and 17.1 months for the induction, CRT and consolidation groups, respectively (p = 0.021). The median overall survival (OS) was 17.6, 13.8 and 25.2 months for the induction, CRT and consolidation groups, respectively (p = 0.001). CONCLUSIONS The patients with T4N2M0 NSCLC who were treated with chemoradiotherapy followed by consolidation chemotherapy had the best outcome in terms of PFS and OS.
Collapse
|